Watch BICX. Know when insiders buy.
One email the day a filing lands. Free.
BICX
BioCorRx Inc.
0.21
−0.03 −12.08%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
0
FLAG · shorts 0
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $6.3MP/E —DIV YIELD —FCF YIELD —REV TTM $787K +151.2%NET INCOME −$3.2MNET CASH $111K52W 0.15 – 0.50SEC XBRL · TTM TO Invalid Date
How BICX rewrote its risk factors
Text kept
86%
of sentences unchanged
Added
20
new sentences
Dropped
13
sentences removed
Length
+138
words, now 6,305
New in FY2025
- For the year ended December 31, 2025, the Company had a loss from operations of $3,508,763 and negative cash flows from operations of $2,298,291.
- Our audited consolidated financial statements for the year ended December 31, 2025 were prepared under the assumption that we would continue our operations as a going concern.
- Our independent registered public accounting firm has included a “going concern” explanatory paragraph in its report on our financial statements for the year ended December 31, 2025.
- The Company anticipates that it will continue to incur operating losses as it executes its development plans for 2026, as well as other potential strategic and business development initiatives.
- Although we have successfully completed equity financings in the past, we cannot assure you that our plans to address these matters in the future will be successful.
- During the year ended December 31, 2025, we recorded a net loss applicable to common shareholders of $3,440,146, or ($0.19) per share, as compared with $5,106,124, or ($0.49) per share, of the corresponding year in 2024.
- As of March 31, 2026, approximately 12 licensed providers have agreed to offer the BioCorRx® Recovery Program and approximately 8 providers have agreed to offer the UnCraveRx® Weight Loss Management Program.
- Our success is substantially dependent on the continued service of our President, Louis Lucido, and our Chief Executive Officer and Chief Financial Officer (“CEO” and “CFO”, respectively), Lourdes Felix.
- Our two officers (whom also serve as directors) and five non-employee directors currently own approximately 66.50% of our outstanding voting equity and has significant control over shareholder matters, such as election of directors, amendments to its Articles of Incorporation, and approval of significant corporate transactions; as a result, the Company’s minority shareholders will have little or no control over its affairs.
- During the year ended December 31, 2025, the Company recognized grant income of $2,435,848 as compared to $1,473,276 for the comparable year last year.
- We feel grant income may potentially be a significant portion of our other income in fiscal year 2026 based on: On March 1, 2024, the Company’s subsidiary BioCorRx Pharmaceuticals Inc. was awarded a grant of $11,029,977 from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA").
- We revised certain previously issued interim financial statement amounts, which could adversely affect investor confidence.
- In preparing our consolidated financial statements for the year ended December 31, 2025, management identified errors in certain previously issued unaudited condensed consolidated financial statements for interim periods during 2025.
- The Company revised the affected amounts to correct these errors.
- Although management concluded that these errors were not material to the previously issued interim financial statements, revisions to previously issued financial information may cause investors to question the accuracy of our financial reporting or the effectiveness of our internal controls.
- This perception could adversely affect investor confidence in the Company and our financial reporting processes.
- In addition, such revisions could result in regulatory inquiries or litigation.
- Any such matters, whether successful or not, could result in additional costs, divert management’s attention, or harm our reputation.
- Our Common Stock is quoted on the OTCID Marketplace and there is not now, nor has there been, any significant market for shares of our Common Stock, and an active trading market for our shares may never develop or be sustained.
- In addition to global macroeconomic effects, the COVID-19 outbreak and any other related adverse public health developments will cause disruption to our operations, research and development, and sales activities.
Gone since FY2024
- For the year ended December 31, 2024, the Company had a loss from operations of $5,122,505 and negative cash flows from operations of $1,096,254.
- Our audited consolidated financial statements for the year ended December 31, 2024 were prepared under the assumption that we would continue our operations as a going concern.
- Our independent registered public accounting firm has included a “going concern” explanatory paragraph in its report on our financial statements for the year ended December 31, 2024.
- The Company anticipates that it will continue to incur operating losses as it executes its development plans for 2025, as well as other potential strategic and business development initiatives.
- Although we have successfully completed equity financings and reduced expenses in the past, we cannot assure you that our plans to address these matters in the future will be successful.
- During the year ended December 31, 2024, we recorded a net loss applicable to common shareholders of $5,106,124, or ($0.49) per share, as compared with $3,766,913, or ($0.45) per share, of the corresponding year in 2023.
- As of March 31, 2025, approximately 12 licensed providers have agreed to offer the BioCorRx® Recovery Program and approximately 8 providers have agreed to offer the UnCraveRx® Weight Loss Management Program.
- Our success is substantially dependent on the continued service of our (“President”) President, Louis Lucido, and our Chief Executive Officer and Chief Financial Officer (“CEO” and “CFO”, respectively), Lourdes Felix.
- Our two officers (whom also serve as directors) and five non-employee directors currently own approximately66.50% of our outstanding voting equity and has significant control over shareholder matters, such as election of directors, amendments to its Articles of Incorporation, and approval of significant corporate transactions; as a result, the Company’s minority shareholders will have little or no control over its affairs.
- During the year ended December 31, 2024, the Company recognized grant income of $1,473,276 as compared to $932,996 for the comparable year last year.
- We feel grant income may potentially be a significant portion of our other income in fiscal year 2025 based on: On March 1, 2024, the Company’s subsidiary BioCorRx Pharmaceuticals Inc. was awarded a grant of $11,029,977 from the National Institutes of Health’s National Institute on Drug Abuse, ("NIDA").
- Our Common Stock is quoted on the OTCQB Marketplace and there is not now, nor has there been, any significant market for shares of our Common Stock, and an active trading market for our shares may never develop or be sustained.
- In addition to global macroeconomic effects, the COVID-19outbreak and any other related adverse public health developments will cause disruption to our operations, research and development, and sales activities.
Sentence-level comparison of Item 1A in the two most recent 10-Ks (FY2024 ↗, FY2025 ↗). A reworded sentence counts as one dropped and one added, so heavy edits read as low “kept”. Headings and page furniture are stripped; nothing is summarised by a model.